Jigs Chemical sourcing supplying API, Active pharmaceutical ingredients intermediates, global generics, Pharma Raw Materials, industrial & Specialty Chemicals. our offices at USA, UK, CANADA, AUSTRALIA. generics, Pharma Raw Materials
Indication: Gefitinib is often used for treating advanced or metastatic NSCLC, especially in cases where the cancer cells have specific mutations in the EGFR gene. It's usually prescribed when other treatments, like chemotherapy, have not been effective.
Mechanism of Action: Gefitinib specifically targets and inhibits the EGFR tyrosine kinase activity. EGFR is involved in signaling pathways that promote cancer cell growth and survival. By blocking this pathway, gefitinib helps to slow down or stop the growth of cancer cells.
Administration: Gefitinib is typically taken orally in the form of tablets. The dosage and frequency depend on the specific condition being treated and the patient's overall health.
Side Effects: Common side effects include diarrhea, rash, nausea, and fatigue. More serious side effects can include liver problems, interstitial lung disease, and severe skin reactions. Regular monitoring by a healthcare provider is essential to manage these risks.
Resistance: Over time, some cancers may develop resistance to gefitinib, often due to further mutations in the EGFR gene or other changes in the cancer cells. In such cases, alternative treatments or additional therapies may be considered.
Generic Name: Gefitinib
Brand Name: Iressa
Drug Class: Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor
Route of Administration: Oral
Forms: Tablets (usually 250 mg)
Gefitinib targets the EGFR, which is a receptor on the surface of cancer cells involved in the signaling pathways that regulate cell growth and division. By inhibiting the tyrosine kinase activity of EGFR, gefitinib:
Blocks Signal Transduction: Interferes with the signals that promote cancer cell proliferation and survival.
Induces Apoptosis: Promotes programmed cell death of cancer cells.
Interstitial Lung Disease (ILD): Symptoms may include difficulty breathing, cough, and fever.
Hepatotoxicity: Elevated liver enzymes indicating possible liver damage.
Severe Skin Reactions: Including severe rash or exfoliative dermatitis.
 
Sihauli Chemicals is one of the leading Gefitinib Manufacturer and Exporter form India. Sihauli Chemicals Supply Gefitinib to Asia, Africa, Europe, North & South America and Oceania.
Our Global Presense:
Asia: Bangladesh, Burma (Myanmar), China, Hong Kong (UK), Indonesia, Iran, Israel, Japan, Jordan, Kampuchea (Cambodia), Kuwait, Laos, Lebanon, Macao (Portuguese), Malaysia, Maldives, Mongolia, Nepal, Oman, Philippines, Qatar, Saudi Arabia, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Turkey, United Arab Emirates, Vietnam.
Europe: Albania, Andorra, Austria, Belgium, Bulgaria, Cyprus, Czechoslovakia, Denmark, Finland, France, German Democratic Republic, Gibraltar, Greece, Hungary, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Spain, Sweden, Switzerland, United Kingdom, U.S.S.R., Yugoslavia. Africa: Algeria, Angola, Egypt, Ethiopia, Gabon, Ghana, Kenya, Liberia, Libya, Madagascar, Mauritius, Morocco, Mozambique, Namibia, Nigeria, Reunion (France), Seychelles, Somalia, South Africa, Sudan, Tanzania, Tunisia, Uganda, Zambia, Zimbabwe.
North America: Bahamas, Barbados, Bermuda, British Virgin Islands, Canada, Costa Rica, Cuba, Dominica, El Salvador, Greenland (Denmark), Grenada, Guatemala, Haiti, Honduras, Jamaica, Martinique, Mexico, Montserrat, Nicaragua, Panama, Puerto Rico (USA), St. Vincent & the Grenadines, Trinidad & Tobago, USA, Virgin Islands.
South America: Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Venezuela.
Oceania: Australia, New Zealand, Solomon Islands, Wallis & Futuna Islands (France).